Last checked at 29 Apr 2016 07:00
29 April 2016
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 31 March 2016
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2016 was 10.21 pence per share, including un-invested cash of £10,713. The portfolio is valued under IFRS at bid price.
Net Assets stand at £2.4 million including Investments of £2.38 million. This quarter's NAV represents a decrease of 5.37% from the previous valuation of 10.79 pence per share, which included un-invested cash of £24,011. No additional management fee is due to Shellbay Investments Limited."
Unaudited to 31 March 2016 (£) | ||
Fixed Assets | ||
Investments | 2,375,370 | |
Current Assets | ||
Sundry Debtors | 34,522 | |
Uninvested cash | 10,713 | |
Current Liabilities | ||
Creditors: amounts due | (51,777) | |
2,368,828 | ||
Capital and Reserves | ||
Share Capital | 23 | |
Share Premium | 1,890,142 | |
Reserves | 478,663 | |
2,368,828 | ||
Shares in Issue | 23,195,558 | |
Net Asset Value per share | 10.21 pence |
Portfolio Details
Investments as at 31 March 2016 | Value | % of Total Portfolio | |
Magna Biopharma Income Fund | £1,093,235 | 46.0% | |
Regent Pacific Group | £600,945 | 25.3% | |
Summit Corporation | £251,293 | 10.6% | |
Other quoted holdings | £96,082 | 4.0% | |
Other unquoted holdings | £333,815 | 14.1% | |
Total | £2,375,370 | 100.0% | |
For further information, please contact:
Port Erin Biopharma Investments Limited | Northland Capital Partners Limited | Peterhouse Capital Limited |
The Company | Nomad and Joint Broker | Broker |
Denham Eke (+44) (0) 1624 639396 | Matthew Johnson/David Hignell (+44) (0) 203 861 6625 | Lucy Williams (+44) (0) 207 469 0936 |